In his written evidence, Mark Mildred (chair of the Skipton Fund Appeals Panel) noted in relation to intravenous drug use: "More extensive disclosure and oral evidence tested by cross-examination might have given a more detailed picture and a better informed basis for the assessment of credibility but these were not open to us."